Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vytrus BiotechXMAD:VYT 71 Debt-to-EBITDA is 0.48 as of Dec. 2025, which is 78% below its 10-year median of 2.15. GuruFocus rates XMAD:VYT with a GF Score™ of 71/100 and a GF Value™ of €5.63 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 298 Biotechnology companies, Vytrus Biotech ranks better than 64.77% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vytrus Biotech's Debt-to-EBITDA or its related term are showing as below:
XMAD:VYT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.48 Med: 2.15 Max: 9.27
Current: 0.48
During the past 8 years, the highest Debt-to-EBITDA Ratio of Vytrus Biotech was 9.27. The lowest was 0.48. And the median was 2.15.
XMAD:VYT's Debt-to-EBITDA is ranked better than 64.77% of 298
companies
in the Biotechnology industry
Industry Median: 1.15
vs XMAD:VYT: 0.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vytrus Biotech Debt-to-EBITDA Related Terms
Vytrus Biotech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Vytrus Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Vytrus Biotech (XMAD:VYT) has a Debt-to-EBITDA of 0.48 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vytrus Biotech. This is 78% below median its historical median of 2.15. Over the past decade, Vytrus Biotech's Debt-to-EBITDA has ranged from 0.48 to 9.27. According to the industry distribution chart, Vytrus Biotech ranks #105 out of 298 companies in the Biotechnology industry, placing it in the top 35.2%.
Is Vytrus Biotech's Debt-to-EBITDA too high?
Vytrus Biotech's current Debt-to-EBITDA of 0.48 is 78% below median its 10-year median of 2.15. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 9.27. The Biotechnology industry median Debt-to-EBITDA is 1.15. Vytrus Biotech's value of 0.48 is 58.3% below this industry median. Based on the distribution chart, Vytrus Biotech ranks #105 out of 298 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #105 out of 298 companies for Debt-to-EBITDA. This puts Vytrus Biotech in the upper half of its industry. The industry median Debt-to-EBITDA is 1.15. Vytrus Biotech's value of 0.48 is 58.3% below this benchmark. Historically, Vytrus Biotech's own Debt-to-EBITDA has ranged from 0.48 to 9.27 over the past decade. While the company's 10-year median is 2.15 vs. the industry median of 1.15, Vytrus Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current Debt-to-EBITDA of 0.48 is 58.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vytrus Biotech. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current Debt-to-EBITDA is 0.48, which is 78% below median its own 10-year median of 2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.63, compared to a current price of €17.60 — trading 212.6% above its estimated fair value. The current Debt-to-EBITDA is 0.48, which is 78% below median its 10-year median of 2.15 and 58.3% below the Biotechnology industry median of 1.15. Vytrus Biotech's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Debt-to-EBITDA is 0.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.60 is trading 212.6% above its estimated GF Value™ of €5.63.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
Debt-to-EBITDA: 0.48 (78% below median its 10-year median of 2.15)
GF Value™: €5.63 vs. price of €17.60 (212.6% above fair value)
Industry Position: 58.3% below the Biotechnology median (#105 of 298)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
71GF Score
Get the complete analysis for XMAD:VYT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
